Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent has acquired Sigsense Technologies, a startup that uses artificial intelligence and power monitoring to optimize lab operations.

Agilent Acquires Sigsense, Creator of AI-Enabled Lab Operations Technology

Agilent (A) unveils its new ProteoAnalyzer system in a bid to strengthen its Diagnostics and Genomics Group segment.

Agilent (A) Boosts DCG Segment With New ProteoAnalyzer System

Agilent Technologies said on Monday it will acquire contract drug manufacturer Biovectra for $925 million to expand its portfolio of services offered to biotech companies and medical researchers.

Agilent to buy contract drug manufacturer Biovectra for $925 million

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent has signed a definitive agreement to acquire BIOVECTRA, a leading contract development and manufacturing organization, for $925 million.

Agilent to Acquire North American CDMO BIOVECTRA

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2024 after the stock market closes on Aug. 21. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent.

Agilent to Announce Third-Quarter Fiscal Year 2024 Financial Results Aug. 21

Intuitive Surgical

UnitedHealth Group

Intuitive Surgical's game-changing robotic surgical systems should continue fueling considerable growth for the business. UnitedHealth is in an excellent position to benefit from the health insurance industry's long-term growth.

History Says These Could Be 3 of the Best Healthcare Stocks to Own in the Second Half of 2024

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced Bret DiMarco has been named to lead the company's global legal organization as senior vice president and chief legal officer, as well as serving as secretary. He begins his new role with Agilent effective today. “Bret DiMarco is another outstanding addition to the Agilent leadership team,” said Padraig McDonnell, Agilent president and CEO. “Bret's broad range of tactical and strategic experience across a.

Agilent Names Bret DiMarco Chief Legal Officer

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Why Is Agilent (A) Down 0.5% Since Last Earnings Report?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today released the company's annual ESG report, showcasing a comprehensive and growing set of sustainable solutions that enable hundreds of thousands of labs worldwide to reduce consumption of nonrenewable resources and to minimize waste. Agilent's sustainable solutions include the sector's largest instrument recycling and refurbishment program and an expanding number of My Green Lab ACT-labeled products that account for.

Agilent's ESG Report Highlights Expansion of Solutions to Help Labs Manage Their Environmental Footprint

B&G Foods

Avis Budget Group

A, CAR and BGS have been added to the Zacks Rank #5 (Strong Sell) List on June 7, 2024.

New Strong Sell Stocks for June 7th

Agilent (A) boosts its presence in the mass spectrometry market with the launch of the Agilent 7010D Triple Quadrupole GC/MS System and the Agilent ExD Cell.

Agilent (A) Boosts Reach to Lab Researchers With New Devices

Agilent Technologies, Inc. (NYSE:A ) Jefferies 2024 Global Healthcare Conference June 5, 2024 8:30 AM ET Company Participants Robert McMahon - Senior Vice President and Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson All right, we're good to go. Good morning, everyone.

Agilent Technologies, Inc. (A) Jefferies 2024 Global Healthcare Conference (Transcript)

Inhibrx Biosciences Inc

Exact Sciences

Teladoc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

San Francisco, California--(Newsfile Corp. - June 4, 2024) -  ePrep is delighted to announce a new partnership with Agilent - a global leader in technology platforms for analytical laboratories - for the distribution of the ePrep® ONE workstation in selected regions. The ePrep ONE is a fully automated solution for end-to-end chromatography sample preparation, which Agilent will be supplying alongside its extensive portfolio of laboratory instruments.

ePrep and Agilent Announce New Distribution Partnership for the ePrep(R) ONE Chromatography Sample Preparation Workstation

Examine the evolution of Agilent's (A) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Investing in Agilent (A)? Don't Miss Assessing Its International Revenue Trends

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc., (NYSE: A) is introducing two new products at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics. The Agilent 7010D Triple Quadrupole GC/MS System which targets the food and environmental markets, offers precision and sensitivity in gas chromatography-mass spectrometry. Additionally, the Agilent ExD Cell for use with the 6545XT AdvanceBio LC/Q-TOF system, serves the biopharma market and life science research. These ins.

Agilent Announces Cutting-Edge Advances in GC/MS and LC/Q-TOF Technology at ASMS 2024

Agilent's (A) fiscal second-quarter results reflect weak momentum across all end markets.

Agilent (A) Q2 Earnings Beat Estimates, Revenues Fall Y/Y

Agilent Technologies, Inc. (NYSE:A ) Q2 2024 Results Conference Call May 29, 2024 4:30 PM ET Company Participants Parmeet Ahuja - Investor Relations Padraig McDonnell - President & Chief Executive Officer Bob McMahon - Senior Vice President & Chief Financial Officer Phil Binns - President of Agilent Life Sciences & Applied Markets Group Simon May - President of the Agilent Diagnostics and Genomics Group Angelica Riemann - President of Agilent CrossLab Group Conference Call Participants Matt Sykes - Goldman Sachs Jack Meehan - Nephron Research Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Doug Schenkel - Wolfe Research Michael Ryskin - Bank of America Dan Arias - Stifel Josh Waldman - Cleeland Research Catherine Schulte - Baird Paul Knight - KeyBanc Operator Ladies and gentlemen, welcome to the Agilent Technologies Q2 2024 Earnings Call. My name is Regina, and I will be coordinating your call today.

Agilent Technologies, Inc. (A) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Agilent (A) give a sense of how the business performed in the quarter ended April 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Agilent (A) Reports Q2 Earnings: What Key Metrics Have to Say

Agilent Technologies (A) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $1.27 per share a year ago.

Agilent Technologies (A) Surpasses Q2 Earnings Estimates

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.57 billion for the second quarter ended April 30, 2024, a decline of 8.4% reported and 7.4% core(1) compared to the second quarter of 2023. Second-quarter GAAP net income was $308 million, or $1.05 per share. This compares with $302 million, or $1.02 per share, in the second quarter of fiscal year 2023. Non-GAAP(2) net income was $356 million, or $1.22 per share during the quarter, compared wi.

Agilent Reports Second-Quarter Fiscal Year 2024 Financial Results

Agilent Technologies' (A) second-quarter fiscal 2024 results are likely to reflect solid momentum across the ACG & DGG segments amid softness in the LSAG segment.

Agilent (A) to Report Q2 Earnings: What's in the Offing?

AGCO

Applied Materials

D.R. Horton

EOG Resources

Imperial Oil

JPMorgan Chase & Co

NextEra Energy

NRG Energy

Owens Corning

PulteGroup

QUALCOMM

Steel Dynamics

Texas Instruments

Advanced Drainage Systems

W. R. Berkley

We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate a sustainable and repeatable income strategy for Options. In this monthly series, we present how to select the right kind of stocks for options income. We present two lists of 10 stocks with multiple scenarios: PUT options and deep-in-the-money CALL options.

Monthly Options Series: Earn A Potentially Consistent 10% Income (June 2024)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Hans E. Bishop, president and co-founder of Altos Labs, has stepped down from serving on Agilent's board of directors. Bishop joined Agilent's board in July 2017, after holding a range of leadership positions in the pharmaceutical industry. “Hans' extensive life science industry leadership and insight have been of great value to the board. We are grateful for his contributions over the past seven year.

Agilent Announces Hans E. Bishop Has Stepped Down from Board of Directors

Evaluate the expected performance of Agilent (A) for the quarter ended April 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

News for Agilent Technologies Stock (A)